The state of Kentucky currently has 75 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including Louisville, Lexington, Owensboro and Paducah.
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Recruiting
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: University of Kentucky - Markey Cancer Center, Lexington, Kentucky
Conditions: Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers
Recruiting
The objective of this prospective phase II protocol is to assess the toxicity and efficacy of pentoxifylline and SABR in the re-treatment of recurrent or new lung cancers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: James Graham Brown Cancer Center, U of Louisville, Louisville, Kentucky
Conditions: Non-small Cell Lung Cancers
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Recruiting
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to t... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
10/04/2023
Locations: Saint Elizabeth Healthcare, Edgewood, Kentucky +1 locations
Conditions: Non-small Cell Lung Cancer